ArticleFrontiers in public health2026
Novel inflammatory metabolic parameters as predictors of metabolic dysfunction-associated fatty liver disease in people living with HIV receiving antiretroviral therapy: a retrospective cohort study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment of a Risk Prediction Model for Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV in China.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a major non-communicable comorbidity in people living with HIV (PLWH). The role of inflammatory metabolic parameters-including the lymphocyte-to-high-density lipoprotein cholesterol ratio (LHR), platelet to high-density lipoprotein cholesterol ratio (PHR), and aggregate index of systemic inflammation (AISI)-in predicting MAFLD in PLWH remains unclear. This study aimed to evaluate the prognostic value of inflammatory metabolic parameters for predicting MAFLD in PLWH. Methods: We conducted a retrospective cohort study of 814 PLWH receiving stable antiretroviral therapy (ART) between 2018 and 2025 at a tertiary care center. Baseline demographic, clinical, and laboratory data were collected. LHR, PHR, and AISI were calculated and categorized into tertiles. The primary outcome was incident MAFLD, diagnosed according to Chinese guidelines. Kaplan-Meier survival analysis, Cox proportional hazards regression, restricted cubic spline (RCS) models, and time-dependent receiver operating characteristic (ROC) curves were applied to assess associations and predictive performance. Sensitivity analyses were performed across subgroups. Results: During a median follow-up of 2.8 years, 116 participants (14.3%) developed MAFLD, corresponding to an incidence rate of 50.4 per 1,000 person-years. Higher LHR and PHR tertiles were significantly associated with increased MAFLD risk, whereas AISI showed no predictive value. In fully adjusted Cox models, the high LHR tertile remained an independent risk factor (HR = 2.315, 95% CI: 1.208-4.436, Conclusion: In this large cohort of PLWH on ART, LHR and PHR were independent predictors of incident MAFLD, with LHR demonstrating the strongest and most consistent predictive value. AISI was not associated with MAFLD. LHR and PHR, as simple, low-cost indices derived from routine laboratory tests, may serve as practical tools for identifying high-risk individuals who could benefit from early monitoring and targeted intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.